Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Nov 20;5(11):e1536. doi: 10.1038/cddis.2014.500

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Macmillan Publishers Limited

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International Licence. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons licence, users will need to obtain permission from the licence holder to reproduce the material. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0

PMC Copyright notice

Combination simvastatin and metformin treatment significantly inhibits C4-2B metastatic CRPC cell viability. (a) Percentage cell viability (mean±S.D.) by the methylene blue assay in C4-2B3 and C4-2B4 cells following treatment with 4 μM simvastatin (SIM) and/or 2 mM metformin (MET) for 24−96 h, n=3 per treatment group. *P<0.05, **P<0.01, ***P<0.001 determined by ANOVA followed by the Tukey multiple comparison procedure where a=untreated, b=SIM, c=MET, and d=SIM+MET in comparisons. (b) Light microscope images at × 10 and × 40 magnification of untreated and combination 4 μM SIM and 2 mM MET-treated C4-2B3 and C4-2B4 cells at 24−72 h (96 h not shown as only 2−6% of SIM+MET-treated C4-2B cells remain viable at that time point)